Inflammatory Bowel Disease Following IL-17 Inhibitor Exposure for Psoriatic Disease and Hidradenitis Suppurativa: A Systematic Review

Abstract

Keywords

humans hidradenitis suppurativa psoriasis psoriatic arthritis inflammatory dermatoses inflammatory bowel disease Crohn’s disease ulcerative colitis IL-17 inhibitors

Get full access to this article

View all access options for this article.

References

Dyrda

Vannabouathong

Peter

, et al Utilization of old- versus new-generation biologics for plaque psoriasis for public and private payers in Canada: technology review [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2022. https://www.ncbi.nlm.nih.gov/books/NBK603629/

Reich

Leonardi

Langley

, et al Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: a presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. J Am Acad Dermatol. 2017;76(3):441-448.e2. doi:10.1016/j.jaad.2016.10.027

Schneeweiss

Kirchgesner

Wyss

, et al Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study: classification: epidemiology. Br J Dermatol. 2022;187(5):692-703. doi:10.1111/bjd.21704

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB